Fuller Douglas S, Dluzniewski Paul J, Cooper Kerry, Bradbury Brian D, Robinson Bruce M, Tentori Francesca
Arbor Research Collaborative for Health, Ann Arbor, MI, USA.
Center for Observational Research, Amgen, Thousand Oaks, CA, USA.
Clin Kidney J. 2019 Nov 8;13(6):1056-1062. doi: 10.1093/ckj/sfz112. eCollection 2020 Dec.
Prior studies have developed a chronic kidney disease-mineral and bone disorder (CKD-MBD) composite score based on combinations of calcium (Ca), phosphorus (P) and parathyroid hormone (PTH) that have been shown to be associated with an increased risk of clinical outcomes in the USA. We examined this association in a contemporary, international cohort of hemodialysis patients.
We studied 19 313 patients surviving ≥12 months in the Dialysis Outcomes and Practice Patterns Study Phases 3-5 (2005-15) from Europe, Canada and the USA. The CKD-MBD composite score was defined as the number of markers above target levels (P, 3.5-5.5 mg/dL; Ca, 8.4-10.2 mg/dL; PTH, 150-600 pg/mL). Using Cox models, we estimated hazard ratios (HRs) for death and a composite event (death or hospitalization), contrasting MBD 2/3 (2-3 parameters above target) with MBD 0 (all in target), adjusted for a disease risk score (DRS).
MBD 2/3 above target was observed in 10-14% of patients across regions and was associated with greater DRS-adjusted mortality {HR 1.41 [95% confidence interval (CI) 1.10-1.82]} and composite events [HR 1.23 (95% CI 1.10-1.38)] in the USA compared with MBD 0; the mortality association was stronger for patients ≥ 65 years of age [HR 1.82 (95% CI 1.28-2.58)] compared with patients <65 years of age [HR 1.11 (95% CI 0.80-1.55)]. HRs observed in Canada and Europe were generally consistent but weaker. Estimates for MBD 2/3 outside target (above or below) were slightly lower in all regions.
Simultaneous consideration of Ca, P and PTH may help in identifying patients on dialysis with a higher risk of major clinical outcomes related to CKD-MBD.
先前的研究基于钙(Ca)、磷(P)和甲状旁腺激素(PTH)的组合制定了慢性肾脏病-矿物质和骨异常(CKD-MBD)综合评分,在美国,这些组合已被证明与临床结局风险增加相关。我们在一个当代国际血液透析患者队列中研究了这种关联。
我们研究了来自欧洲、加拿大和美国的透析预后与实践模式研究第3-5阶段(2005-2015年)中存活≥12个月的19313例患者。CKD-MBD综合评分定义为高于目标水平的标志物数量(P,3.5-5.5mg/dL;Ca,8.4-10.2mg/dL;PTH,150-600pg/mL)。使用Cox模型,我们估计了死亡和复合事件(死亡或住院)的风险比(HR),将MBD 2/3(2-3个参数高于目标)与MBD 0(所有参数均在目标范围内)进行对比,并根据疾病风险评分(DRS)进行调整。
各地区10%-14%的患者出现高于目标的MBD 2/3,与MBD 0相比,在美国,MBD 2/3与更高的经DRS调整的死亡率{HR 1.41[95%置信区间(CI)1.10-1.82]}和复合事件[HR 1.23(95%CI 1.10-1.38)]相关;与年龄<65岁的患者[HR 1.11(95%CI 0.80-1.55)]相比,65岁及以上患者的死亡率关联更强[HR 1.82(95%CI 1.28-2.58)]。在加拿大和欧洲观察到的HR总体一致,但较弱。所有地区高于或低于目标的MBD 2/3的估计值略低。
同时考虑Ca、P和PTH可能有助于识别血液透析患者中与CKD-MBD相关的主要临床结局风险较高的患者。